Art. 2 Directive (EU) 2004/27

In forcesince 31 Mar 2004cited 10×

The periods of protection provided for in Article 1, point 8, which amends Article 10(1) of Directive 2001/83/EC, shall not apply to reference medicinal products for which an application for authorisation has been submitted before the date of transposition referred to in Article 3 first paragraph.

  • Judgment of the Court (First Chamber) of 9 June 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/03 to C-318/03) Decision

    That interpretation is supported by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC (OJ 2004 L 136, p. 34), although the period for transposition of that directive does not …

    9 Jun 2005 · 62003CJ0211

  • Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision

    Artikel 2 van die richtlijn, zoals gewijzigd bij richtlijn 2004/27, luidt: „1. Deze richtlijn is van toepassing op geneesmiddelen voor menselijk gebruik, bestemd om in de lidstaten in de handel te worden gebracht, die industrieel of door …

    13 Mar 2014 · 62012CJ0512

  • Opinion of Mr Advocate General Mazák delivered on 26 March 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    According to Articles 2 and 3 of Directive 2004/27, where the application for authorisation was made before 30 October 2005, the applicable period of protection is that laid down in Article 10 of Directive 2001/83 prior to its amendment by …

    26 Mar 2009 · 62007CC0527

  • Judgment of the Court (Third Chamber) of 16 July 2015. Abcur AB v Apoteket Farmaci AB and Apoteket AB.Decision

    … приготвените лекарствени продукти, а и — след изменението ѝ с член 2 от Директива 2004/27 — за първоначално необхванатите от нея …

    16 Jul 2015 · 62013CJ0544

  • Judgment of the Court (First Chamber) of 18 June 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision

    According to Articles 2 and 3 of Directive 2004/27, where the application for authorisation was made before 30 October 2005, the applicable period of protection is that laid down in Article 10 of Directive 2001/83 prior to its amendment by …

    18 Jun 2009 · 62007CJ0527

  • Opinion of Mr Advocate General Geelhoed delivered on 3 February 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/Decision

    Firstly, static demarcation issues. These arise whenever, with respect to its objectively ascertainable characteristics, a product falls both under the definition of medicinal product as described in Article 1(2) of Directive 2001/83 and …

    3 Feb 2005 · 62003CC0211

  • Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision

    The data exclusivity period is currently eight years. [In principle and subject to a transitional regime: reference is often made to the ‘8 + 2 formula’, which comprises eight years of data protection (during which the applicant for a …

    7 Dec 2017 · 62016CC0557

  • BGH, Urteil vom 5. Oktober 2010 - I ZR 90/08Decision

    … Da kein Zweifelsfall vorliege, führe auch die Regelung in Art. 2 Abs. 2 der Richtlinie 2004/27/EG zu keinem anderen Ergebnis.

    5 Oct 2010 · KORE301182010

  • Opinion of Advocate General Campos Sánchez-Bordona delivered on 30 January 2025. SALUS Haus Dr. med Otto Greither Nachf. GmbH & Co.KG v AstrDecision

    The interpretation which I propose is also consistent with the European approach to regulating medicinal products, which tends to reject the double legal classification of products (and the consequent diversity of regimes) which fit the …

    30 Jan 2025 · 62023CC0618

  • BGH, Urteil vom 5. Oktober 2010 - I ZR 90/08Decision

    5 Oct 2010 · I_ZR__90-08